Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 7Neuromyelitis Optica 2Recurrence 1Optic Neuritis 1Myelitis, Transverse 1Hemoglobinuria, Paroxysmal 1Demyelinating Diseases 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

eculizumab 3ravulizumab 2fludarabine 2Cyclophosphamide 2ublituximab 1thymoglobulin 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Sugars 1Rituximab 1Prednisone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Melphalan 1LFB-R603 1Immunoglobulins, Intravenous 1Etoposide 1Data Collection 1Cytarabine 1Carmustine 1Antilymphocyte Serum 1Alleles 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuromyelitis Optica × ravulizumab × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT04201262 2025-10-14

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
58 enrolled 19 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚔